search

IBBL IMIIMI is the world’s biggest public-private partnership in the field of life sciences. The initiative has a budget of €3.3 billion for the period 2014-2020 with which it funds research aiming to speed up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. On 14 December 2018, its first 10 years of funding medical breakthrough will be celebrated by an international conference and networking event taking place in Luxembourg.

IBBL is taking part in two IMI projects, LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) and CANCER-ID (Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood). LITMUS aims to develop and validate highly accurate blood tests and imaging techniques that will allow doctors and researchers to rapidly and easily diagnose the severity of the disease in individual patients and monitor changes in their livers. The objective of CANCER-ID is to develop new, less invasive ways of capturing cancerous cells and cancer genetic material from blood samples and analysing them for clues to what treatment is needed and how well drugs are working. The project focuses initially on specific types of lung and breast cancer.

Luxinnovation discussed with Kristin Kornerup, Project manager at IBBL, about the biobank’s involvement in the projects.

IBBL IMIWhat is IBBL’s contribution to these two IMI projects?

IBBL has been chosen as the central biobank of LITMUS. As such, it will gather all the biological samples currently stored at the other partners’ sites. IBBL will also serve as the central collection and storage site for the samples that will be freshly collected for the LITMUS project from at least 1,500 patients across Europe. We will store blood, plasma, serum, DNA, RNA, urine, stool and liver biopsies and create a catalogue of the samples and associated data to be made available to the research community.

In CANCER-ID, IBBL contributes to the validation of laboratory methods, the development of standard operating procedures and the development of a proficiency testing programme.

 

What kind of results are you aiming for? How do they translate to Luxembourg?

The aim of CANCER-ID is to validate the use of specific blood-based biomarkers for the early diagnosis of cancer. In addition, these could help in monitoring the efficacy of treatment, as well as helping clinicians with choosing the right treatment for the right patient at the right time.

At the national level, IBBL will bring its expertise in biobanking and biomarker validation to the EU consortia, thus increasing Luxembourg’s visibility and strengthening its reputation as a centre of excellence among internationally-renowned universities, SMEs and pharmaceutical companies. Ultimately, the results of the projects will translate into better healthcare both for European and Luxembourgish patients.

What does the IMI participation bring to IBBL?

Given the competitiveness of IMI grants, IBBL is very proud to have been selected as a partner of these two prestigious consortia. Our participation in the projects further confirms our international reputation as a reliable, quality-driven biobank and a valuable partner. Our involvement in two IMI grants has contributed to strengthening our network of partners and our growing portfolio of European and international projects.

Pictures: © IBBL

Read more

Hannover Messe 2019: call for Participation

18-12-2018

For the next edition of the international trade fair Hannover Messe, which will take place from 1st to 5th April 2019 in Hanover, the Chamber of Commerce is planning to set up a Luxembourg collective stand. Companies interested in participating have until 21st December to make themselves known.
Read more

Circular Economy: EU public consultation on a product policy framework

13-12-2018

The EU has opened a public consultation help identify in how far the current EU product policy framework supports a circular economy and the potential for increasing this contribution. Input is needed from the general public, businesses and local authorities as well as other stakeholders.
Read more

Luxembourg research wins an ERC Consolidator Grant 2018

07-12-2018

The European Research Council announced the recipients of its Consolidator Grant competition: 291 top scientists across Europe, including one Luxembourgish. Funding for these researchers, part of the Horizon 2020 research and innovation programme, is worth in total €573 million and will give them a chance to build up their teams and have far-reaching impact
Read more

Luxinnovation and Maison Moderne are proud to announce the publication of the second issue of Happen

29-11-2018

Happen is an annual business magazine that unveils the technological excellence and innovative spirit of Luxembourg and its companies to an international audience.
Read more

Innovative Medicines Initiative: Consolidating Luxembourg expertise in translational medicine research

22-11-2018

With the development of new informatics tools, medical and life sciences research is rapidly evolving. This gives research centres unprecedented opportunities to analyse medical data. The Bioinformatics Core’s team (and Luxembourg’s ELIXIR-LU Node) at the interdisciplinary Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg is building the skills and tools needed to make this happen.
Read more

All news

Fermer